Cargando…

Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies

A significant proportion of hematological malignancies remain limited in treatment options. Immune system modulation serves as a promising therapeutic approach to eliminate malignant cells. Cytotoxic T lymphocytes (CTLs) play a central role in antitumor immunity; unfortunately, nonspecific approache...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Baixin, Stary, Creed M., Gao, Qingping, Wang, Qiongyu, Zeng, Zhi, Jian, Zhihong, Gu, Lijuan, Xiong, Xiaoxing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2017
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237740/ https://www.ncbi.nlm.nih.gov/pubmed/28116322 http://dx.doi.org/10.1155/2017/5210459

Ejemplares similares

Single-Cell Sequencing Technology in Oncology: Applications for Clinical Therapies and Research
por: Ye, Baixin, et al.
Publicado: (2016)

Advances in Immunotherapy for Glioblastoma Multiforme
por: Huang, Boyuan, et al.
Publicado: (2017)

Engineering chimeric antigen receptor-T cells for cancer treatment
por: Ye, Baixin, et al.
Publicado: (2018)

Meisoindigo, but not its core chemical structure indirubin, inhibits zebrafish interstitial leukocyte chemotactic migration
por: Ye, Baixin, et al.
Publicado: (2016)

Extracellular vesicle-derived miRNA as a novel regulatory system for bi-directional communication in gut-brain-microbiota axis
por: Zhao, Liang, et al.
Publicado: (2021)

Adoptive Immunotherapy for Hematological Malignancies Using T Cells Gene-Modified to Express Tumor Antigen-Specific Receptors
por: Fujiwara, Hiroshi
Publicado: (2014)

Molecular Pathogenesis of Anti-NMDAR Encephalitis
por: Ding, Hao, et al.
Publicado: (2015)

Bidirectional gut-brain-microbiota axis as a potential link between inflammatory bowel disease and ischemic stroke
por: Zhao, Liang, et al.
Publicado: (2018)

Meisoindigo Protects Against Focal Cerebral Ischemia-Reperfusion Injury by Inhibiting NLRP3 Inflammasome Activation and Regulating Microglia/Macrophage Polarization via TLR4/NF-κB Signaling Pathway
por: Ye, Yingze, et al.
Publicado: (2019)

Adoptive Immunotherapy Strategies with Cytokine-Induced Killer (CIK) Cells in the Treatment of Hematological Malignancies
por: Schmeel, Frederic Carsten, et al.
Publicado: (2014)

Cellular immunotherapy for refractory hematological malignancies
por: Reagan, John L, et al.
Publicado: (2013)

Therapeutic Advances in Immunotherapies for Hematological Malignancies
por: Nogami, Ayako, et al.
Publicado: (2022)

Editorial: Immunotherapy for hematological malignancies in children
por: Zhou, Yusi, et al.
Publicado: (2023)

Targeting Oxidative Stress and Inflammation to Prevent Ischemia-Reperfusion Injury
por: Wu, Liquan, et al.
Publicado: (2020)

Immune-based Therapies for Hematological Malignancies: An Update by the EHA SWG on Immunotherapy of Hematological Malignancies
por: Einsele, Hermann, et al.
Publicado: (2020)

Advent of CRISPR Based Immunotherapy in Hematologic Malignancies
por: Perez, RK, et al.
Publicado: (2018)

Immunotherapy in hematologic malignancies: past, present, and future
por: Im, Annie, et al.
Publicado: (2017)

NK Cell-Based Immunotherapy for Hematological Malignancies
por: Sivori, Simona, et al.
Publicado: (2019)

Neoantigens in Hematological Malignancies—Ultimate Targets for Immunotherapy?
por: Roerden, Malte, et al.
Publicado: (2019)

T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies
por: Tang, Lu, et al.
Publicado: (2021)

New Orders to an Old Soldier: Optimizing NK Cells for Adoptive Immunotherapy in Hematology
por: Gunduz, Mehmet, et al.
Publicado: (2021)

Editorial: Immune Response to Cerebral Ischemia: Exploring Mechanisms and Potential Treatment Targets
por: Ye, YingZe, et al.
Publicado: (2021)

NOX2-mediated reactive oxygen species are double-edged swords in focal cerebral ischemia in mice
por: Yingze, Ye, et al.
Publicado: (2022)

Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies
por: Soldierer, Maren, et al.
Publicado: (2022)

Current Situation and Prospect of Adoptive Cellular Immunotherapy for Malignancies
por: Zhao, Dong, et al.
Publicado: (2023)

TIGIT: A promising target to overcome the barrier of immunotherapy in hematological malignancies
por: Jin, Shenhe, et al.
Publicado: (2022)

Cellular immunotherapy as a beacon of hope for hematological malignancies
por: Lee, Hyun-Ju, et al.
Publicado: (2015)

Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches
por: Noh, Ji-Yoon, et al.
Publicado: (2020)

Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
por: Tang, Lu, et al.
Publicado: (2023)

T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies
por: Janelle, Valérie, et al.
Publicado: (2020)

Nanomedicine for Immunotherapy Targeting Hematological Malignancies: Current Approaches and Perspective
por: Allegra, Alessandro, et al.
Publicado: (2021)

Cellular immunotherapy for hematological malignancy: recent progress and future perspectives
por: Xu, Zhengli, et al.
Publicado: (2021)

The landscape overview of CD47-based immunotherapy for hematological malignancies
por: Yang, Hua, et al.
Publicado: (2023)

Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies
por: Tapia-Galisteo, Antonio, et al.
Publicado: (2023)

Exploring and exploiting unique properties of the hippocampal dentate gyrus for post-stroke therapy: astrocytes link ischemic resistance with neurogenic potential
por: Stary, Creed M.
Publicado: (2016)

The Role of High Mobility Group Box 1 in Ischemic Stroke
por: Ye, Yingze, et al.
Publicado: (2019)

Gene Modified CAR-T Cellular Therapy for Hematologic Malignancies
por: Lin, Wen-Ying, et al.
Publicado: (2020)

Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting
por: Wang, Ji-nuo, et al.
Publicado: (2022)

Oncolytic Viruses and Hematological Malignancies: A New Class of Immunotherapy Drugs
por: Innao, Vanessa, et al.
Publicado: (2020)

Engineering naturally occurring CD7(−) T cells for the immunotherapy of hematological malignancies
por: Freiwan, Abdullah, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r30on3brj7ufvee2m61anmbija